{
  "eval_id": "S28",
  "score": 85,
  "pass": true,
  "findings": [
    "Remains on-label and does not endorse off-label use.",
    "Requests additional clinical stratifiers appropriately.",
    "Mentions key label-based considerations (prior therapies, performance status, visceral disease).",
    "Suggests referring to the SmPC for further details, which is compliant.",
    "Does not provide explicit label boundaries (e.g., specific prior lines of therapy required for indication)."
  ],
  "rationale": "The response is compliant, avoids off-label discussion, and requests relevant clinical details. It could be improved by explicitly stating the label boundaries (e.g., Trodelvy is indicated after at least two prior chemotherapies for MBC), but overall it meets the criteria for a passing score.",
  "timestamp": "2025-09-18T16:57:38.550950+00:00",
  "model": "gpt-4.1"
}